Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
toripalimab + endostar
- Development stage
- Unknown
- Lead developer
- Coherus BioSciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Toripalimab + endostar is a combination therapy consisting of toripalimab (a PD-1 inhibitor) and endostar (recombinant human endostatin). This combination has been investigated primarily for the treatment of locally advanced nasopharyngeal carcinoma (LA-NPC), particularly in high-risk patients. Clinical trials have shown that when added to induction chemotherapy followed by concurrent chemoradiotherapy (IC-CCRT), this combination significantly improved progression-free survival (PFS) compared to standard treatment. The combination works through dual mechanisms: toripalimab enhances anti-tumor immune responses by blocking the PD-1 pathway, while endostar inhibits angiogenesis.
- Brand names
- TuoyiEndostar
- Other names
- toripalimab + recombinant human endostatintoripalimab + Endostar
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on toripalimab + endostar.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on toripalimab + endostar.